Filovirus disease: including Ebola disease, Marburg disease, and unspecified and emergent filovirus diseases. Infections and Infestations
Conditions
Interventions
This is a multi-country, multi-outbreak randomised adaptive platform trial of potential treatments for filovirus disease. This includes Ebola disease, Marburg disease, and unspecified and emergent fil
Sponsors
World Health Organization
Ministry of Health
Eligibility
Sex/Gender
All
Age
0 Days to 110 Years
Inclusion criteria
Inclusion criteria: 1. Admitted to a hospital or treatment unit for treatment of filovirus disease 2. Positive Filovirus RT-PCR (or neonate aged 7 days or younger born to a woman with acute laboratory-confirmed Filovirus Disease) 3. No medical history that might, in the opinion of the attending clinician, put the patient at significant risk if enrolled in the trial (e.g. known allergy to a study drug) 4. Not known to have been enrolled in this protocol previously
Exclusion criteria
Exclusion criteria: Not meeting the participant inclusion criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| All-cause mortality measured using patient medical records at 28 days following randomisation | — |
Secondary
| Measure | Time frame |
|---|---|
| Time (days) to Filovirus RNA <LLOQ (lower limit of quantitation) measured using real time reverse transcription-polymerase chain reaction within 28 days following randomisation | — |
Countries
Congo, Democratic Republic, Rwanda
Contacts
Public ContactVaseeharan Sathiyamoorthy
Outcome results
None listed